Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Basilea Pharmaceutica AG
  6. News
  7. Summary
    BSLN   CH0011432447

BASILEA PHARMACEUTICA AG

(BSLN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Basilea Seeks US FDA's Investigational New Drug Approval For Cancer Therapy

11/16/2021 | 01:32am EST


ę MT Newswires 2021
All news about BASILEA PHARMACEUTICA AG
01/24Basilea Pharmaceutica's Derazantinib Shows High Disease Control Rate in Bile Duct Cance..
MT
01/24BASILEA PHARMACEUTICA : Updated January 24, 2022
PU
01/24Basilea reports updated interim results for iCCA patients with FGFR2 mutations and ampl..
DJ
01/24Basilea Reports Updated Interim Results for iCCA Patients with FGFR2 Mutations and Ampl..
CI
01/13Basilea-Pfizer's Cresemba Gets China's Approval to Treat Another Fungal Infection
MT
01/13Basilea announces approval of antifungal Cresemba« (isavuconazole) for invasive aspergi..
AQ
01/13Basilea announces approval of antifungal Cresemba(R) (isavuconazole) for invasive asper..
DJ
01/11Basilea Completes Patient Enrolment For New Antibiotic Study
MT
01/11BASILEA PHARMACEUTICA : Updated January 11, 2022
PU
01/11Basilea announces completion of patient enrolment in phase 3 ERADICATE study investigat..
DJ
More news
Analyst Recommendations on BASILEA PHARMACEUTICA AG
More recommendations
Financials
Sales 2021 141 M 152 M 152 M
Net income 2021 -22,2 M -23,9 M -23,9 M
Net cash 2021 0,85 M 0,92 M 0,92 M
P/E ratio 2021 -21,9x
Yield 2021 -
Capitalization 516 M 554 M 554 M
EV / Sales 2021 3,64x
EV / Sales 2022 3,33x
Nbr of Employees 160
Free-Float 87,5%
Chart BASILEA PHARMACEUTICA AG
Duration : Period :
Basilea Pharmaceutica AG Technical Analysis Chart | BSLN | CH0011432447 | MarketScreener
Technical analysis trends BASILEA PHARMACEUTICA AG
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 43,50 CHF
Average target price 85,00 CHF
Spread / Average Target 95,4%
EPS Revisions
Managers and Directors
David Veitch Chief Executive Officer
Adesh Kaul Head-Corporate Development
Domenico Scala Chairman
Laurenz Kellenberger Chief Scientific Officer
Marc Engelhardt Head-Clinical Research
Sector and Competitors
1st jan.Capi. (M$)
BASILEA PHARMACEUTICA AG7.23%559
MODERNA, INC.-41.48%60 258
LONZA GROUP AG-19.46%48 939
IQVIA HOLDINGS INC.-17.77%44 321
SEAGEN INC.-20.50%22 475
ICON PUBLIC LIMITED COMPANY-17.13%20 892